A detailed history of Northern Trust Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 584,584 shares of AKRO stock, worth $19.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
584,584
Previous 587,866 0.56%
Holding current value
$19.1 Million
Previous $13.8 Million 21.61%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.45 - $29.34 $70,398 - $96,293
-3,282 Reduced 0.56%
584,584 $16.8 Million
Q2 2024

Aug 14, 2024

SELL
$18.31 - $24.62 $179,840 - $241,817
-9,822 Reduced 1.64%
587,866 $13.8 Million
Q1 2024

May 14, 2024

BUY
$17.76 - $31.18 $1.01 Million - $1.78 Million
57,003 Added 10.54%
597,688 $15.1 Million
Q4 2023

Feb 13, 2024

BUY
$11.38 - $50.33 $30,293 - $133,978
2,662 Added 0.49%
540,685 $12.6 Million
Q3 2023

Nov 13, 2023

BUY
$41.19 - $52.25 $3.2 Million - $4.05 Million
77,594 Added 16.85%
538,023 $27.2 Million
Q2 2023

Aug 11, 2023

BUY
$36.89 - $56.88 $3.79 Million - $5.84 Million
102,662 Added 28.7%
460,429 $21.5 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $93,547 - $126,102
-2,510 Reduced 0.7%
357,767 $13.7 Million
Q4 2022

Feb 13, 2023

BUY
$33.44 - $54.8 $3.2 Million - $5.25 Million
95,767 Added 36.21%
360,277 $19.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $205,354 - $688,899
20,232 Added 8.28%
264,510 $9.01 Million
Q2 2022

Aug 12, 2022

BUY
$8.0 - $15.01 $66,824 - $125,378
8,353 Added 3.54%
244,278 $2.31 Million
Q1 2022

May 13, 2022

SELL
$12.97 - $22.26 $179,621 - $308,278
-13,849 Reduced 5.54%
235,925 $3.35 Million
Q4 2021

Feb 08, 2022

BUY
$19.87 - $26.24 $56,251 - $74,285
2,831 Added 1.15%
249,774 $5.28 Million
Q3 2021

Nov 15, 2021

SELL
$18.65 - $25.46 $187,786 - $256,356
-10,069 Reduced 3.92%
246,943 $5.52 Million
Q2 2021

Aug 13, 2021

BUY
$24.81 - $32.35 $2.06 Million - $2.69 Million
83,012 Added 47.71%
257,012 $6.38 Million
Q1 2021

May 12, 2021

SELL
$24.04 - $34.19 $311,750 - $443,375
-12,968 Reduced 6.94%
174,000 $5.05 Million
Q4 2020

Feb 11, 2021

SELL
$25.12 - $29.89 $128,513 - $152,917
-5,116 Reduced 2.66%
186,968 $4.82 Million
Q3 2020

Nov 16, 2020

BUY
$30.79 - $39.92 $1.17 Million - $1.52 Million
38,032 Added 24.69%
192,084 $5.91 Million
Q2 2020

Aug 14, 2020

BUY
$19.25 - $26.76 $1.04 Million - $1.45 Million
54,190 Added 54.26%
154,052 $3.84 Million
Q1 2020

May 14, 2020

BUY
$12.8 - $27.05 $392,972 - $830,462
30,701 Added 44.39%
99,862 $2.12 Million
Q4 2019

Feb 14, 2020

SELL
$17.37 - $27.27 $13,461 - $21,134
-775 Reduced 1.11%
69,161 $1.54 Million
Q3 2019

Nov 13, 2019

BUY
$16.89 - $29.88 $989,889 - $1.75 Million
58,608 Added 517.37%
69,936 $1.59 Million
Q2 2019

Aug 13, 2019

BUY
$18.08 - $19.83 $204,810 - $224,634
11,328 New
11,328 $217,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.